Secretary Kennedy Expands Newborn Screenings to Include Duchenne and Metachromatic Leukodystrophy
Recent advancements in newborn screening have been announced by Secretary of Health and Human Services, Robert F. Kennedy, Jr. On December 16, 2025, Kennedy approved the inclusion of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) into the Recommended Uniform Screening Panel (RUSP). This decision follows thorough scientific review and public input.
Importance of Early Detection
Early detection of DMD and MLD is crucial. It allows access to FDA-approved therapies that can significantly slow disease progression. Secretary Kennedy emphasized the importance of timely care, quoting his uncle, “children may be the victims of fate, they will not be the victims of our neglect.” This initiative aims to ensure children receive effective treatment promptly.
Screening Benefits
Currently, most children with DMD or MLD are diagnosed between four to five years old. By then, they may have already experienced significant muscle loss or functional decline. Adding these conditions to the RUSP ensures that:
- Children retain their abilities for a longer period.
- Families avoid lengthy diagnostic searches and associated emotional and financial strains.
- They receive crucial information for making informed health decisions at an early stage.
Tom Engels, HRSA Administrator, remarked that early diagnosis transforms the treatment journey for affected children, replacing years of uncertainty with clear options.
Support from Lawmakers
Several congressional members expressed their support during the announcement. Senator Katie Britt (R-AL) highlighted the importance of the RUSP update for parental decision-making and the hope it brings to families. Senator Roger Wicker (R-MS) shared insights about his long-standing commitment to combatting DMD and noted how earlier testing positively impacts lives.
Senator Ron Johnson (R-WI) praised the initiative for granting families access to potential treatment options. Congressman Gus Bilirakis (R-FL) described the announcement as a breakthrough in health care, underscoring the significance of early identification in improving treatment outcomes.
Looking Ahead
The HHS will continue to support states in implementing these screenings. The goal is to evaluate how early detection can enhance health outcomes for children affected by rare diseases like DMD and MLD. This initiative marks a significant step forward in pediatric healthcare, promising improved prospects for some of the most vulnerable members of society.
